Table 3.
Baseline characteristics of CAD patients with and without MACE during follow-up.
| Patients without MACE | Patients with MACE | P | |
|---|---|---|---|
| Total, n | 358 | 145 | |
| Male, n (%) | 240 (67.04%) | 118 (81.38%) | 0.001 |
| Age, y (mean ± SD) | 58.52 ± 11.58 | 61.75 ± 11.05 | 0.004 |
| Hypertension (%) | 188 (52.51%) | 93 (64.14%) | 0.018 |
| DM (%) | 77 (21.51%) | 52 (35.86%) | 0.001 |
| Smoking (%) | 159 (44.41%) | 84 (57.93%) | 0.008 |
| SBp (mmHg) | 125.79 ± 23.71 | 125.34 ± 21.64 | 0.843 |
| DBp (mmHg) | 78.73 ± 14.16 | 78.39 ± 14.01 | 0.802 |
| HR (beats/min) | 73.44 ± 16.92 | 71.37 ± 16.79 | 0.212 |
| BMI (kg/m2) | 24.63 ± 2.71 | 25.20 ± 3.22 | 0.045 |
| LVEF (%) | 57.58 ± 12.03 | 55.54 ± 11.79 | 0.085 |
| Hs-CRP (mg/L) | 5.76 ± 2.24 | 6.34 ± 3.64 | 0.029 |
| TC (mmol/L) | 3.91 ± 0.95 | 4.09 ± 0.99 | 0.060 |
| TG (mmol/L) | 1.69 ± 0.72 | 1.73 ± 0.82 | 0.590 |
| HDL-C (mmol/L) | 0.99 ± 0.25 | 0.88 ± 0.22 | <0.001 |
| LDL-C (mmol/L) | 2.26 ± 0.74 | 2.51 ± 0.87 | 0.001 |
| ACE-I/ARB, n (%) | 247 (68.99%) | 96 (66.21%) | 0.527 |
| Statins, n (%) | 343 (95.81%) | 134 (92.41%) | 0.124 |
| β-blocker, n (%) | 246 (68.72%) | 105 (72.41%) | 0.454 |
| Aspirin, n (%) | 344 (96.09%) | 137 (94.48%) | 0.471 |
CAD: coronary artery disease; MACE: major adverse cardiacevent; SBp: systolic blood pressure; DBp: diastolic blood pressure; HR: heart rate; BMI: body mass index; LVEF: left ventricular ejection fraction; Hs-CRP: high-sensitivity C-reactive protein; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; DM: diabetes mellitus; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor antagonist.